← Leaderboards
Chengfei Liu
Pandomedx, Inc.
$5,761,190
Attributed
$5,761,190
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $931.6K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,761,190 · 5
By mechanism
R01$1,783,175 · 1
R37$1,770,550 · 1
R44$1,504,319 · 1
R21$403,160 · 1
R43$299,986 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cancer Patient”
- David Heimbrook · Leidos Biomedical Research, Inc.$436,176,488
- Larry Arthur$370,429,903
- Norman Wolmark · Nsabp Foundation, Inc.$324,028,859
- Gregory H Reaman · National Childhood Cancer Foundation$270,366,096
- Leonard Freedman · Leidos Biomedical Research, Inc.$268,085,841
- Richard A Gibbs · Baylor College Of Medicine$240,560,484
Research focus
Cancer PatientMalignant Neoplasm Of ProstateResistanceAbirateroneAndrogen ReceptorAndrogen AntagonistsVariantPharmaceutical PreparationsResistance MechanismPrimary NeoplasmProteinsProstate Cancer CellSmall MoleculePatient Derived Xenograft ModelMulticatalytic Endopeptidase ComplexNext GenerationChronicDrug ResistanceIn VitroIn VivoPathway InteractionsClinically RelevantEffective TherapyPharmacologic Substance
Grant awards (15)
Dissecting the Role of Proteostasis in Anti-Androgen Resistant Prostate Cancer$359,138
R37 · FY2025 · CA · contact PI
Modulating HSP70/STUB1 machinery in therapy-resistant prostate cancer$359,098
R01 · FY2025 · CA · contact PI
Modulating HSP70/STUB1 machinery in therapy-resistant prostate cancer$344,129
R01 · FY2024 · CA · contact PI
Dissecting the Role of Proteostasis in Anti-Androgen Resistant Prostate Cancer$341,181
R37 · FY2024 · CA · contact PI
Targeting intracrine steroidogenesis in anti-androgen resistant prostate cancer$178,760
R21 · FY2024 · CA · contact PI
Modulating HSP70/STUB1 machinery in therapy-resistant prostate cancer$355,216
R01 · FY2023 · CA · contact PI
Dissecting the Role of Proteostasis in Anti-Androgen Resistant Prostate Cancer$351,955
R37 · FY2023 · CA · contact PI
Targeting intracrine steroidogenesis in anti-androgen resistant prostate cancer$224,400
R21 · FY2023 · CA · contact PI
Modulating HSP70/STUB1 machinery in therapy-resistant prostate cancer$362,398
R01 · FY2022 · CA · contact PI
Dissecting the Role of Proteostasis in Anti-Androgen Resistant Prostate Cancer$359,138
R37 · FY2022 · CA · contact PI
Modulating HSP70/STUB1 machinery in therapy-resistant prostate cancer$362,334
R01 · FY2021 · CA · contact PI
Dissecting the Role of Proteostasis in Anti-Androgen Resistant Prostate Cancer$359,138
R37 · FY2021 · CA · contact PI
A Phase II trial of abiraterone in combination with PDMX1001 in enzalutamide-resistant prostate cancer$750,000
R44 · FY2019 · CA · contact PI
A Phase II trial of abiraterone in combination with PDMX1001 in enzalutamide-resistant prostate cancer$754,319
R44 · FY2018 · CA · contact PI
A Phase Ib clinical trial with niclosamide plus abiraterone for Castration Resistant Prostate Cancer (CRPC)$299,986
R43 · FY2016 · CA · contact PI